Peger Biopharmaceutical-B (02565) plans to discount 10% of the placement for a total of 5.136 million shares to raise about HK$296 million

According to the Zhitong Finance App, Peger Biopharmaceutical-B (02565) announced that on December 12, 2025 (after the trading period), the Company entered into a placement agreement with the Joint Placement Agent. According to this, the Company has agreed to place a total of 5.136,000 placement shares to no less than six undertakers at a price of HK$58.41 per share on a best-effort basis. Such placement shares will be issued by the Company under general authorization in accordance with the terms and conditions set out in the placement agreement.

Assuming that there is no change in the issued share capital of the Company between the date of this announcement and the date of completion, the total number of 5.136,000 placed shares is equivalent to: (i) approximately 1.84% of the H shares issued and about 1.33% of the total number of issued shares; and (ii) approximately 1.81% of the H shares expanded through allotment and issuance of the placed shares and approximately 1.31% of the total number of shares. The placement price is HK$58.41 per share, a 10% discount on the closing price of H shares of HK$64.90 per share reported on the Stock Exchange on December 12, 2025 (Hong Kong time) (the date of the placement agreement).

Assuming that all placed shares are fully placed, the estimated total proceeds from the placement and net proceeds (after deducting related costs and expenses to be borne by the Company) would be approximately HK$300 million and approximately HK$296 million respectively. Among them: 1.40% to build a next-generation intelligent R&D and data platform; 2. About 28% to repay loans and strengthen the company's capital structure; 3.12%, to continue and plan to develop PB-2301 and PB-2309; 4. About 10% to establish Hong Kong subsidiaries and accelerate the Group's overseas business layout; 5. 10%, for general corporate use and working capital.